Literature DB >> 16552622

Reduced glioma infiltration in Src-deficient mice.

Caren V Lund1, Mai T N Nguyen, Geoffrey C Owens, Andrew J Pakchoian, Ashkaun Shaterian, Carol A Kruse, Brian P Eliceiri.   

Abstract

Malignant brain tumors, such as glioblastoma, are characterized by extensive angiogenesis and permeability of the blood-brain barrier (BBB). The infiltration of glioma cells away from the primary tumor mass is a pathological characteristic of glial tumors. The infiltrating tumor cells represent a significant factor in tumor recurrence following surgical debulking, radiation, and chemotherapy treatments. Vascular endothelial growth factor (VEGF)-mediated vascular permeability (VP) has been associated with the progression of glioma tumor growth and infiltration into surrounding normal brain parenchyma. While VEGF induces a robust VP response in control mice (src+/+ or src+/-), the VP response is blocked in src-/- mice that demonstrate a 'leakage-resistant phenotype' in the brain. We used the Src-deficient mouse model to determine the role of Src in the maintenance of the BBB following orthotopic implantation and growth of glioma cells in the brain. Although solid tumor growth was the same in control and src-/- mice, the infiltrating component of glioma growth was reduced in src-/- mice. Characterization of the expression and localization of the extracellular matrix (ECM) protein fibrinogen was evaluated to determine the effect of a Src-mediated VP defect in the host compartment. These studies indicate that the reduced VP of host brain blood vessels of src-/- mice mediates a reduction in glioma cell invasion in a mouse brain tumor xenograft model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552622      PMCID: PMC4002283          DOI: 10.1007/s11060-005-9068-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  76 in total

Review 1.  "...those left behind." Biology and oncology of invasive glioma cells.

Authors:  M E Berens; A Giese
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

2.  Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia.

Authors:  Zheng Gang Zhang; Li Zhang; Wayne Tsang; Hamid Soltanian-Zadeh; Daniel Morris; Ruilan Zhang; Anton Goussev; Cecylia Powers; Thomas Yeich; Michael Chopp
Journal:  J Cereb Blood Flow Metab       Date:  2002-04       Impact factor: 6.200

3.  Migratory patterns of lac-z transfected human glioma cells in the rat brain.

Authors:  P H Pedersen; K Edvardsen; I Garcia-Cabrera; R Mahesparan; J Thorsen; B Mathisen; M L Rosenblum; R Bjerkvig
Journal:  Int J Cancer       Date:  1995-09-15       Impact factor: 7.396

4.  Exploiting the lacZ reporter gene for quantitative analysis of disseminated tumor growth within the brain: use of the lacZ gene product as a tumor antigen, for evaluation of antigenic modulation, and to facilitate image analysis of tumor growth in situ.

Authors:  L A Lampson; M A Lampson; A D Dunne
Journal:  Cancer Res       Date:  1993-01-01       Impact factor: 12.701

Review 5.  Molecular mechanisms of glioma cell migration and invasion.

Authors:  Tim Demuth; Michael E Berens
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

6.  Experiment and observation on invasion of brain glioma in vivo.

Authors:  Xiang Zhang; Xia Li; Jing-wen Wu; Da-kuan Gao; Jing-wen Liang; Xian-zhen Liu
Journal:  J Clin Neurosci       Date:  2002-11       Impact factor: 1.961

7.  Glioblastoma cells release factors that disrupt blood-brain barrier features.

Authors:  Stefan W Schneider; Thomas Ludwig; Lars Tatenhorst; Stephan Braune; Hans Oberleithner; Volker Senner; Werner Paulus
Journal:  Acta Neuropathol       Date:  2004-01-17       Impact factor: 17.088

8.  Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases.

Authors:  Nor Eddine Sounni; Christian Roghi; Vincent Chabottaux; Mathias Janssen; Carine Munaut; Erik Maquoi; Beatriz G Galvez; Christine Gilles; Francis Frankenne; Gillian Murphy; Jean-Michel Foidart; Agnès Noel
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

9.  SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling.

Authors:  M A Westhoff; B Serrels; V J Fincham; M C Frame; N O Carragher
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas.

Authors:  Roxane Oliveira; Christo Christov; Jean Sébastien Guillamo; Sophie de Boüard; Stéphane Palfi; Laurent Venance; Marcienne Tardy; Marc Peschanski
Journal:  BMC Cell Biol       Date:  2005-02-16       Impact factor: 4.241

View more
  24 in total

1.  Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.

Authors:  David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine B Peters; Sith Sathornsumetee; Stevie Threatt; John H Sampson; James E Herndon; April Coan; Frances McSherry; Jeremy N Rich; Roger E McLendon; Steven Zhang; Henry S Friedman
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Src family kinases differentially influence glioma growth and motility.

Authors:  Laura J Lewis-Tuffin; Ryan Feathers; Priya Hari; Nisha Durand; Zhimin Li; Fausto J Rodriguez; Katie Bakken; Brett Carlson; Mark Schroeder; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  Mol Oncol       Date:  2015-06-10       Impact factor: 6.603

3.  In vivo measurement of glioma-induced vascular permeability.

Authors:  Jisook Lee; Andrew Baird; Brian P Eliceiri
Journal:  Methods Mol Biol       Date:  2011

4.  Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma.

Authors:  Jisook Lee; Alexandra K Borboa; Hyun Bae Chun; Andrew Baird; Brian P Eliceiri
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.

Authors:  Jennie W Taylor; Jorg Dietrich; Elizabeth R Gerstner; Andrew D Norden; Mikael L Rinne; Daniel P Cahill; Anat Stemmer-Rachamimov; Patrick Y Wen; Rebecca A Betensky; Diana H Giorgio; Kellis Snodgrass; Alison E Randall; Tracy T Batchelor; Andrew S Chi
Journal:  J Neurooncol       Date:  2014-11-20       Impact factor: 4.130

Review 6.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

7.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Authors:  Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Authors:  Vita M Golubovskaya; Grace Huang; Baotran Ho; Michael Yemma; Carl D Morrison; Jisook Lee; Brian P Eliceiri; William G Cance
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

Review 9.  Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.

Authors:  John de Groot; Vanessa Milano
Journal:  J Neurooncol       Date:  2009-05-13       Impact factor: 4.130

10.  Identification of key signaling molecules involved in the activation of the swelling-activated chloride current in human glioblastoma cells.

Authors:  Luigi Catacuzzeno; Antonio Michelucci; Luigi Sforna; Francesco Aiello; Miriam Sciaccaluga; Bernard Fioretti; Emilia Castigli; Fabio Franciolini
Journal:  J Membr Biol       Date:  2013-11-16       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.